title: Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study.
abstract: Hepatitis B re-infection prophylaxis is crucial for graft and recipient survival for transplanted patients and is administered routinely after liver transplantation for hepatitis B. Aim of the current study was the investigation of efficacy, safety and feasibility of home-treatment of a novel human hepatitis B immunoglobulin BT088 (Zutectra) after weekly subcutaneous application in liver-transplanted patients. A total of 23 patients (5 female, 18 male, median age 51 years) were enrolled and switched from monthly IV to weekly SC hepatitis B immunoglobulin administration. During a period of 18 weeks (optional 24 weeks) anti-HBs levels, signs of re-infection, adverse events and feasibility of self-administration were studied. After 8 weeks of training patients showing good compliance and stable antibody titres were allowed to start self-administration at home. All patients maintained a safety level of >100 U/l anti-HBs. No failure was noted, no re-infection occurred. A total of 10 treatment-emergent events were assessed as related to study drug application (injection-site haematoma, headache, abdominal pain, fatigue and haematuria). High numbers of self-administration (287 vs. 122 by staff) demonstrated general feasibility of SC administration. Weekly subcutaneous administration of BT088 (Zutectra - registered trade mark in the EU) is effective, safe and presents an easy-to-apply treatment option for combined hepatitis B virus re-infection prophylaxis in liver transplant patients (Eudra CT Number: 2005-003737-40).
authors.affiliation: Department of General-, Visceral- and Transplantation Surgery, Charité University Medicine Berlin, Berlin, Germany. ali.yahyazadeh@charite.de
authors.forename: Ali
authors.initials: A
authors.lastname: Yahyazadeh
authors.forename: Susanne
authors.initials: S
authors.lastname: Beckebaum
authors.forename: Vito
authors.initials: V
authors.lastname: Cicinnati
authors.forename: Christian
authors.initials: C
authors.lastname: Klein
authors.forename: Andreas
authors.initials: A
authors.lastname: Paul
authors.forename: Andreas
authors.initials: A
authors.lastname: Pascher
authors.forename: Ruth
authors.initials: R
authors.lastname: Neuhaus
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology; D017277:Drug Approval; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000517:prevention & control; D006515:Hepatitis B virus / Q000378:metabolism*; D006801:Humans; D007136:Immunoglobulins / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D012449:Safety; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; C559911:BT088 immunoglobulin, human; D007136:Immunoglobulins; C045213:hepatitis B hyperimmune globulin